Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations
- König, Marton
- Lorentzen, Åslaug Rudjord
- Torgauten, Hilde Marie
- Tran, The Trung
- Schikora-Rustad, Stine
- Vaage, Eline Benno
- Mygland, Åse Daasvand
- Wergeland, Stig
- Aarseth, Jan Harald
- Aaberge, Ingeborg Sundsvalen
- Torkildsen, Øivind
- Holmøy, Trygve
- Berge, Tone
- Myhr, Kjell-Morten
- Harbo, Hanne-Cathrin Flinstad
- Andersen, Jan Terje
- Munthe, Ludvig Andre
- Søraas, Arne Vasli
- Celius, Elisabeth Gulowsen
- Vaage, John T.
- Lund-Johansen, Fridtjof
- Nygaard, Gro Owren
DOIAbstract
Introduction The effect of disease-modifying therapies (DMT) on vaccine responses is largely unknown. Understanding the development of protective immunity is of paramount importance to fight the COVID-19 pandemic. Objective To characterise humoral immunity after mRNA-COVID-19 vaccination of people with multiple sclerosis (pwMS). Methods All pwMS in Norway fully vaccinated against SARS-CoV-2 were invited to a national screening study. Humoral immunity was assessed by measuring anti-SARS-CoV-2 SPIKE RBD IgG response 3–12 weeks after full vaccination, and compared with healthy subjects. Results 528 pwMS and 627 healthy subjects were included. Reduced humoral immunity (anti-SARS-CoV-2 IgG <70 arbitrary units) was present in 82% and 80%...
Add to ORKG